[ad_1] Biopharma firm MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded to Peer Perform from Outperform at Wolfe Research, citing concerns on overpromised timelines. MLTX down about 2% premarket.…
Browsing: nearterm
[ad_1] Biopharma firm MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded to Peer Perform from Outperform at Wolfe Research, citing concerns on overpromised timelines. MLTX down about 2% premarket.…
[ad_1] Biopharma firm MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded to Peer Perform from Outperform at Wolfe Research, citing concerns on overpromised timelines. MLTX down about 2% premarket.…